MAQUET Cardiovascular Receives CE Mark For INTERGARD SYNERGY Vascular Graft

Informations

• Publié par: wcg
• Nombre de lectures: 24
• Langue: English

Extrait

MAQUET Cardiovascular Receives CE Mark For

INTERGARD SYNERGY Vascular Graft

PR Newswire

WAYNE, New J.ersey, June 19, 2012

WAYNE, New J.ersey,

June 19, 2012

/PRNewswire/ -- MAQUET Cardiovascular,

LLC announced today that it has received CE mark for its INTERGARD SYNERGY

vascular graft. This graft represents the next generation in antimicrobial grafts

combining the well-known antimicrobial properties of silver acetate and

triclosan. The INTERGARD SYNERGY graft will be commercially available

immediately within countries that recognize the CE mark.

Vascular graft infection, although rare, is one of the most serious complications

of vascular reconstructive surgery. Conservative treatment of prosthetic graft

infections is rarely successful and is used only in patients with a high operative

risk or apparently limited infection. Therefore, the most effective strategy

against this severe complication is primary prevention of vascular graft

infection.

"This new INTERGARD SYNERGY uses an interesting approach to fight against

acquired infection in vascular surgery patients. The combination of these two

well-known and effective antimicrobial agents on the vascular graft is

promising. This new infection protection holds the potential to enhance my

ability to ensure that my vascular surgery patients remain infection free,"

stated Max Zegelman, M.D., Ph.D. of Krankenhaus Nordwest,

Frankfurt,

Germany

. "I have long been an advocate of antimicrobial coatings on surgical

prosthesis even though there is not yet evidence-based demonstration of their

impact on overall infection rates. I believe INTERGARD SYNERGY graft is

offering new possibilities."

The INTERGARD SYNERGY graft is designed to help prevent infection by using a

combination of the broad spectrum anti-infective properties of silver and

triclosan, which are released from the surface of the graft to surrounding

tissues following implantation. While silver acetate and triclosan are effective

antimicrobial agents alone, their power to prevent development of infection is

intensified when combined and offers surgeons a vascular graft with increased

antimicrobial properties[1]. In vitro testing of the INTERGARD SYNERGY

vascular graft demonstrates antimicrobial efficacy against a broad spectrum of

micro-organisms including MRSA (Methicillin Resistant Staphylococcus Aureus)

and is substantially more effective than the first generation INTERGARD SILVER

graft [1]-[2].

"The INTERGARD SYNERGY graft is another example of MAQUET

Cardiovascular's commitment to providing customers with new and innovative

solutions that improve patient care for years to come," said Christian Keller,

President and CEO of MAQUET Cardiovascular. "MAQUET's innovative spirit has

allowed us to pioneer the development of vascular graft prostheses with

antimicrobial properties and bring the INTERGARD SYNERGY graft to market."

MAQUET has unparalleled experience in helping to prevent vascular infection

having received the CE mark and launch of its first generation antimicrobial

INTERGARD SILVER graft in 1999. INTERGARD SILVER was the world's first

antimicrobial vascular prosthesis when launched and since that time over

180,000 of this first generation antimicrobial grafts have been implanted in

patients with excellent results.

About MAQUET

As a trusted partner for hospitals and clinicians since 1838, Maquet is a global

leader in medical systems that advance surgical interventions, cardiovascular

procedures and critical care. Maquet develops and designs innovative products

and therapeutic applications for the operating room, hybrid OR/Cath lab,

intensive care unit and patient transport within acute care hospitals, improving

outcomes and quality of life for patients.

Cardiovascular specialties include intra-aortic balloon counterpulsation therapy

for cardiac assist; coronary artery bypass surgery; aortic and peripheral

vascular surgery; and extracorporeal circulation.

The Critical Care portfolio includes market-leading intensive care ventilators

and anesthesia machines.

MAQUET also equips Surgical Workplaces with critical infrastructure such as

flexible room design for OR and ICU; OR tables; lights and ceiling supply units;

and OR integration for image data management.

MAQUET is a subsidiary of the publicly listed Swedish Getinge Group. In 2011,

Maquet generated nearly

1.4 billion Euro

which is more than half of the Group's

annual revenue of

2.4 billion Euros

. The Getinge Group has 13,000 employees

worldwide, including around 6,000 Maquet employees in 50 international sales

and service organizations, as well as a network of more than 280 sales

representatives. For more information please visit www.maquet.com and

www.getingegroup.com.

MAQUET – The Gold Standard.

www.maquet.com

www.getinge.com

[1] Data on file

[2] In vitro evaluation of the antimicrobial efficacy of a new silver-triclosan vs a

silver collagen-coated polyester vascular graft against methicillin-resistant

Staphylococcus aureus. Ricco JB, Assadian A, Schneider F, Assadian O. J Vasc

Surg. 2012 Mar;55(3):823-9. Epub 2011 Nov 10.